China Resources Double-Crane Pharmaceutical's (SHA:600062) subsidiary, CR Double-Crane Limin Pharmaceutical (Jinan), received a drug registration certificate for bosentan dispersible tablets, according to a Shanghai bourse filing on Tuesday.
The pharmaceutical company invested 8.4 million yuan into the research and development of the drug, which was developed to treat pulmonary arterial hypertension.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments